NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer Print E-mail
Monday, 25 September 2017 00:00

AMES, Iowa, Sept. 25, 2017 (GLOBE NEWSWIRE)

AMES, Iowa, Sept. 25, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the .header{height:100px; border-top:10px solid #472558; background:url(; overflow:hidden} combination of background: -webkit-linear-gradient(top, #ededed 0%,#cdcdcd 100%); indoximod, NewLink Genetics’ small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca’s anti-PD-L1 monoclonal antibody, along with standard of background: -o-linear-gradient(top, #ededed 0%,#cdcdcd 100%); care chemotherapy for patients with metastatic pancreatic cancer.

The primary objective for this randomized placebo-controlled, Phase 2 study is to .footer-nav{width: 100%; height:74px; text-align:center; color:#c0c0c0;} evaluate the efficacy and safety of background: -ms-linear-gradient(top, #ededed 0%,#cdcdcd 100%); the .leftblk{float:left; overflow:hidden} immuno-oncology-based combination compared to .footer-nav a{font-size:12px; line-height:74px; color:#c0c0c0; padding: 0 5px; text-decoration:underline} gemcitabine/ABRAXANE alone. Patients will also be enrolled into a smaller cohort evaluating the .leftblk img{float: left; margin-top:22px; *margin-top:18px; padding-right: 15px;} combination of durvalumab with gemcitabine/ABRAXANE.  

The Phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as the .domain_name{float:left; line-height:34px; font-size:26px; font-weight: normal; color:#fff; padding-top:27px; width:535px} study sponsor.  NewLink Genetics’ share of background: linear-gradient(to bottom, #ededed 0%,#cdcdcd 100%); the aggregate expense of filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ededed', endColorstr='#cdcdcd',GradientType=0 ); _background: #ededed} the trial is .container{width:100%} not expected to .footer-nav a:hover{text-decoration: none} have a material effect on its financial position. 

“We are pleased to initiate a joint immuno-oncology clinical collaboration with AstraZeneca,” said Dr. Charles J. Link, Jr., Chairman, Chief Executive Officer and Chief Scientific Officer of NewLink Genetics. “As recent data have indicated, indoximod combinations with immunotherapy and chemotherapy show promise of .content{background:#483d5b; -webkit-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); improving outcomes for patients with multiple tumor types.”

About Durvalumab

Durvalumab (Imfinzi™), a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the #logo{float:right;width:300px;padding:15px 0 0} tumour's immune-evading tactics and inducing an immune response.

Durvalumab is .kwd_bloack{margin-top:0} being assessed in Phase III trials as a monotherapy in various stages of -moz-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); NSCLC, in small-cell lung cancer (SCLC), in metastatic urothelial cancer (mUC) and in head and neck squamous cell carcinoma (HNSCC). The combination of durvalumab and